- United States
- /
- Pharma
- /
- NasdaqCM:NTRB
Nutriband First Quarter 2026 Earnings: EPS Beats Expectations
Nutriband (NASDAQ:NTRB) First Quarter 2026 Results
Key Financial Results
- Revenue: US$667.4k (up 63% from 1Q 2025).
- Net loss: US$1.39m (loss narrowed by 27% from 1Q 2025).
- US$0.13 loss per share (improved from US$0.21 loss in 1Q 2025).
All figures shown in the chart above are for the trailing 12 month (TTM) period

Nutriband EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 25%.
The company's shares are up 19% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 4 warning signs for Nutriband you should be aware of, and 2 of them are significant.
Valuation is complex, but we're here to simplify it.
Discover if Nutriband might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:NTRB
Nutriband
Develops a portfolio of transdermal pharmaceutical products in the United States.
Adequate balance sheet with slight risk.
Similar Companies
Market Insights
Weekly Picks

An Undervalued 3.3Moz Gold Project in Canada
QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

EU#8 - Anheuser-Busch InBev: Courage, Capital, and the Discipline to Build an Empire

The capitalist colossus that makes your parcels magically appear, powers half the internet, and knows your shopping habits.
Recently Updated Narratives
Worth Considering
Bajaj Auto has seen a correction in its stock price after a strong rally, making it an attractive opportunity for investors.

Aussie’s Barton Gold, No Debt Miner with 1 Mill That Changes Everything
Popular Narratives
NVIDIA will see a profit margin surge of 55% in the next 5 years
QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

